PD-1, a programmed death receptor 1, is a member of the b7 protein superfamily, which expressed in some types of tumor cells and in immune cells that infiltrate various types of tumors. .
is a monoclonal antibody that binds to the programmed death receptor (PD-1). By blocking the interaction between PD-1 and its ligand PD-L1 and PD-L2, it blocks the immunosuppressive response mediated by PD-1 pathway. Including anti-tumor immunoreaction. Nivolumab is mainly used in the treatment of melanoma and non-small cell lung cancer.
Immunotherapy of tumor
Normally, the immune system can identify and remove tumor cells from the tumor microenvironment, but in order to survive and grow, tumor cells can adopt different strategies to suppress the immune system of the human body and not kill tumor cells normally. Tumor immunotherapy is a method to control and remove tumor by restarting and maintaining tumor-immune circulation and restoring normal anti-tumor immune response.
Nonsmall-cell lung cancer (NSCLC)
In the clinical study, both NSCLC treated patients and pembrolizumab showed higher activity. Nivolumab could make the total remission rate of NSCLC patients up to 17, and the duration of remission could reach more than 18 months. The total remission rate of NSCLC patients was 21.
Nivolumab and pembrolizumab have significant immunological effects on melanoma. When nivolumab and ipilimumab were used together, the patients benefited greatly. Similarly, the remission rate of the patients was greatly increased to 57.6, nivolumab was 43.7, and the remission rate of ipilimumab was 19.7%.
Products for PD-1 Inhibitor